JAGUAR HEALTH INC (JAGX) Stock News

USA - Nasdaq - NASDAQ:JAGX - US47010C8881 - Common Stock

1.35 USD

+0.07 (+5.47%)

Last: 11/28/2025, 7:40:20 PM

1.3201 USD

-0.03 (-2.21%)

After Hours: 11/28/2025, 7:40:20 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

JAGX Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Chartmill - Mentions: ICON KEYS PLAG SAVA ...

News Image

Get insights into the top gainers and losers of Monday's after-hours session.

12 days ago - By: Chartmill - Mentions: PLUG JACK CANF WKHS ...

News Image

Tuesday's after hours session: top gainers and losers

7 days ago - By: ACCESS Newswire

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

11 days ago - By: ACCESS Newswire

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

11 days ago - By: Benzinga - Mentions: BFLY ZYXI TXMD AGIO ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

14 days ago - By: ACCESS Newswire

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

17 days ago - By: ACCESS Newswire

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

18 days ago - By: ACCESS Newswire

Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting

25 days ago - By: ACCESS Newswire

REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and

a month ago - By: ACCESS Newswire

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Benzinga - Mentions: KIDS VNRX CUE ATHE ...

12 Health Care Stocks Moving In Thursday's After-Market Session

2 months ago - By: ACCESS Newswire

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

2 months ago - By: ACCESS Newswire

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease

2 months ago - By: ACCESS Newswire

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

2 months ago - By: ACCESS Newswire

Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition

2 months ago - By: ACCESS Newswire

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts

3 months ago - By: ACCESS Newswire

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

3 months ago - By: ACCESS Newswire

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

3 months ago - By: ACCESS Newswire

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

3 months ago - By: ACCESS Newswire

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

4 months ago - By: ACCESS Newswire

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

4 months ago - By: ACCESS Newswire

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

5 months ago - By: ACCESS Newswire

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

5 months ago - By: ACCESS Newswire

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS

5 months ago - By: ACCESS Newswire

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

5 months ago - By: Stocktwits

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

5 months ago - By: ACCESS Newswire

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

5 months ago - By: ACCESS Newswire

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

5 months ago - By: ACCESS Newswire

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

5 months ago - By: ACCESS Newswire

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

6 months ago - By: ACCESS Newswire

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

6 months ago - By: ACCESS Newswire

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

6 months ago - By: ACCESS Newswire

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series

6 months ago - By: ACCESS Newswire

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

6 months ago - By: ACCESS Newswire

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners’ Spring 2025 Spotlight Series

6 months ago - By: Stocktwits

Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’